20 September 2012 – Quotient Clinical, a leading provider of specialist early stage drug development services, will present four significant poster publications at the forthcoming American Association of Pharmaceutical Sciences (AAPS) meeting and exposition to be held from October 14th to 18th in Chicago, USA.
The first publication, co-authored with Merck Serono, is entitled Development of a Formulation Design Space to Enable Real-Time Optimization of a Modified Release (MR) Tablet Composition within a Flexible Clinical Study and examines how MR tablet formulations can be developed to enable assessment in humans in a single, flexible RapidFACT™ clinical study to identify an optimal once/twice daily product.
Co-authored with scientists from Ardrea Biosciences and L’Université de Montreal, the second publication entitled Rapid Clinical Screening of a Nanosized Poorly Soluble Drug Substance as an Alternative Means to Achieve Extended Release evaluates a nanosized Immediate Release (IR) tablet formulation as a strategy to achieve a once-a-day product via dissolution-controlled release.
The third publication: Applications of Exploratory Clinical Trials in Drug Development: Review of Exploratory Trial user Group Meeting, Washington DC, June 2011, co-authored with scientists from seven leading pharmaceutical companies; AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Pfizer and Takeda, reviews the proceedings of a user group meeting that discussed the impact of ICH M3 exploratory clinical trials guidance on conventional drug development paradigms.
Co-authored with scientists from GlaxoSmithKline and entitled Applications of the Entero-Test® Bile String for Accessing Biliary Excretion of GSK962040 and its Metabolites in Healthy Subjects, the fourth publication describes the combined application of Quotient’s ivMicrotracerTM technology with Entero-Test® duodenal sampling to study the biliary elimination of GSK962040 (a selective motilin agonist).
Details of the publications are:
Development of a Formulation Design Space to Enable Real-time Optimization of a Modified Release (MR) Tablet
Composition within a Flexible Clinical Study
Poster Session I (Abstract ID: 104, Poster ID: T2130)
Date: Tuesday, October 16, 2012
Time: 09:30am – 12:30pm
Location: Hall F
Rapid Clinical Screening of a Nanosized Poorly Soluble Drug Substance as an Alternative Means to Achieve Extended Release
Poster Session I (Abstract ID: 2419, Poster ID: W5053)
Date: Wednesday, October 17, 2012
Time: 01:30pm – 04:30pm
Location: Hall F
Applications of Exploratory Clinical Trials in Drug Development: Review of Exploratory Trial user Group Meeting,
Washington DC, June 2011
Poster Session I (Abstract ID: 2088 Poster ID: T3349)
Date: Tuesday, October 16, 2012
Time: 01:30pm - 04:30pm
Location: Hall F
Application of the Entero-Test® Bile String for Accessing Biliary Excretion of GSK962040 and its Metabolites in Healthy Subjects
Poster Session II (Abstract ID: 1214, Poster ID: T2307)
Date: Tuesday, October 16, 2012
Time: 09:30am - 12.30pm
Location: Hall F
Quotient will be located at exhibition booth #2530 to discuss your drug product optimization needs. Should you wish to arrange a meeting, please email clinical@quotientbioresearch.com.
Copies of the posters will be made available at www.quotientbioresearch.com/publications/posters.
For further information, please contact:
Sam Metcalf
bcsAgency
Tel: 0115 9486900
Email: quotient@bcsagency.com
About Quotient Clinical
Quotient Clinical, part of Quotient Bioresearch, “Quotient”, has over 20 years’ experience delivering high quality data to provide innovative early drug development solutions to pharmaceutical and biotechnology clients worldwide, including 17 of the top 20 pharmaceutical companies. Our expertise in Exploratory Clinical Pharmacology, Drug Product Optimisation, and 14C Enabled Drug Development, underpinned by our unique Translational Pharmaceutics™ and Synthesis-to-Clinic™ delivery platforms, adds significant value to client development programs.
For further information, visit www.quotientbioresearch.com/clinical.
About Quotient Bioresearch
Quotient Bioresearch is a leading provider of early stage and specialist drug development services to life science clients worldwide. We provide tailored solutions for pharmaceutical, biotechnology and agrochemical clients, using state-of-the-art technologies underpinned by unparalleled medical, chemical and biological expertise. Our consultative, science-driven approach ensures the highest quality service to support and accelerate new product development. Our extensive range of capabilities spans Chemistry and Metabolism, Bioanalytical Sciences, and Clinical. These can be provided independently or integrated into bespoke work programmes.
For additional information or to discuss your specific needs, contact us on info@quotientbioresearch.com or visit www.quotientbioresearch.com.
